QuiaPEG Pharmaceuticals Holding AB (publ) (QUIA.ST)
SEK 0.02
(77.06%)
SEK 0.02
(77.06%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -13.43 Million SEK | -8.09% |
| 2022 | -13.97 Million SEK | 19.14% |
| 2021 | -16 Million SEK | 35.07% |
| 2020 | -23.66 Million SEK | -37.66% |
| 2019 | -17.19 Million SEK | -53.55% |
| 2018 | -11.19 Million SEK | -188.71% |
| 2017 | - SEK | -140.42% |
| 2016 | 9.59 Million SEK | 543.1% |
| 2015 | 441 Thousand SEK | 400.67% |
| 2014 | 298 Thousand SEK | 149.09% |
| 2013 | -607 Thousand SEK | 67.85% |
| 2012 | -1.88 Million SEK | -165.51% |
| 2011 | 2.97 Million SEK | 24.22% |
| 2010 | 1.51 Million SEK | -9.06% |
| 2009 | 2.17 Million SEK | 99.45% |
| 2008 | 1.27 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.56 Million SEK | 0.0% |
| 2024 Q1 | -2.56 Million SEK | 18.99% |
| 2023 Q4 | -3.16 Million SEK | 0.0% |
| 2023 Q1 | -3.55 Million SEK | -25.72% |
| 2023 FY | - SEK | -8.06% |
| 2023 Q2 | -3.55 Million SEK | 0.0% |
| 2023 Q3 | -3.16 Million SEK | 11.04% |
| 2022 FY | - SEK | 19.14% |
| 2022 Q1 | -4.02 Million SEK | 24.32% |
| 2022 Q2 | -3.24 Million SEK | 19.42% |
| 2022 Q4 | -2.82 Million SEK | -21.49% |
| 2022 Q3 | -2.32 Million SEK | 28.29% |
| 2021 Q2 | -3.47 Million SEK | -19.86% |
| 2021 FY | - SEK | 35.07% |
| 2021 Q4 | -5.32 Million SEK | -44.55% |
| 2021 Q1 | -2.89 Million SEK | 49.74% |
| 2021 Q3 | -3.68 Million SEK | -6.08% |
| 2020 Q3 | -8.42 Million SEK | -82.04% |
| 2020 Q2 | -4.62 Million SEK | 4.74% |
| 2020 FY | - SEK | -37.66% |
| 2020 Q1 | -4.85 Million SEK | 0.74% |
| 2020 Q4 | -5.76 Million SEK | 31.62% |
| 2019 FY | - SEK | -53.55% |
| 2019 Q2 | -3.53 Million SEK | -30.01% |
| 2019 Q1 | -2.72 Million SEK | 51.22% |
| 2019 Q4 | -4.89 Million SEK | 18.96% |
| 2019 Q3 | -6.03 Million SEK | -70.61% |
| 2018 Q1 | -1 Million SEK | 4.36% |
| 2018 FY | - SEK | -188.71% |
| 2018 Q4 | -5.58 Million SEK | -279.85% |
| 2018 Q3 | -1.46 Million SEK | 53.19% |
| 2018 Q2 | -3.13 Million SEK | -211.0% |
| 2017 FY | - SEK | -140.42% |
| 2017 Q2 | -1.65 Million SEK | -255.25% |
| 2017 Q3 | -697 Thousand SEK | 57.99% |
| 2017 Q4 | -1.05 Million SEK | -51.36% |
| 2017 Q1 | -467 Thousand SEK | -104.52% |
| 2016 Q1 | -714 Thousand SEK | -25.7% |
| 2016 FY | - SEK | 543.1% |
| 2016 Q3 | -319 Thousand SEK | -208.14% |
| 2016 Q4 | 10.33 Million SEK | 3339.18% |
| 2016 Q2 | 295 Thousand SEK | 141.32% |
| 2015 Q1 | 1.13 Million SEK | 335.61% |
| 2015 Q2 | 395 Thousand SEK | -65.29% |
| 2015 Q4 | -568 Thousand SEK | -120.16% |
| 2015 FY | - SEK | 400.67% |
| 2015 Q3 | -258 Thousand SEK | -165.32% |
| 2014 Q1 | 3.25 Million SEK | 127.74% |
| 2014 FY | - SEK | 149.09% |
| 2014 Q4 | -483 Thousand SEK | -271.28% |
| 2014 Q3 | 282 Thousand SEK | 105.37% |
| 2014 Q2 | -5.25 Million SEK | -261.37% |
| 2013 FY | - SEK | 67.85% |
| 2013 Q4 | -11.73 Million SEK | -204.29% |
| 2013 Q1 | 2.9 Million SEK | 204.72% |
| 2013 Q2 | -3.84 Million SEK | -232.26% |
| 2013 Q3 | 11.24 Million SEK | 392.49% |
| 2012 Q3 | -425 Thousand SEK | 0.0% |
| 2012 Q4 | -2.77 Million SEK | -553.41% |
| 2012 FY | - SEK | -165.51% |
| 2011 Q2 | 977 Thousand SEK | 0.0% |
| 2011 FY | - SEK | 24.22% |
| 2010 Q2 | 813 Thousand SEK | 0.0% |
| 2010 FY | - SEK | -9.06% |
| 2009 Q2 | 330 Thousand SEK | 0.0% |
| 2009 FY | - SEK | 99.45% |
| 2008 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 96.348% |
| AcouSort AB (publ) | -16.7 Million SEK | 19.589% |
| Active Biotech AB (publ) | -43.88 Million SEK | 69.396% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 32079.333% |
| Amniotics AB (publ) | -27.14 Million SEK | 50.518% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | 5.529% |
| BioArctic AB (publ) | 275.38 Million SEK | 104.877% |
| Camurus AB (publ) | 562.54 Million SEK | 102.388% |
| Cantargia AB (publ) | -284.31 Million SEK | 95.276% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 31.401% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 21.385% |
| Genovis AB (publ.) | 64.57 Million SEK | 120.8% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 88.311% |
| Mendus AB (publ) | -97.84 Million SEK | 86.273% |
| Kancera AB (publ) | -61.88 Million SEK | 78.298% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 49.853% |
| LIDDS AB (publ) | -39.67 Million SEK | 66.143% |
| Lipum AB (publ) | -37.11 Million SEK | 63.816% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -10.963% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 142.768% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 671650.0% |
| NextCell Pharma AB | -40.98 Million SEK | 67.23% |
| OncoZenge AB (publ) | 7.26 Million SEK | 284.847% |
| Saniona AB (publ) | -69.69 Million SEK | 80.729% |
| Simris Alg AB (publ) | -22.36 Million SEK | 39.941% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 95.769% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 95.238% |
| Xintela AB (publ) | -53.47 Million SEK | 74.882% |
| Ziccum AB (publ) | -20.34 Million SEK | 33.974% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 63.724% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 92.091% |
| CombiGene AB (publ) | -35.33 Million SEK | 61.991% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 90.464% |
| Intervacc AB (publ) | -68.98 Million SEK | 80.529% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 94.348% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -545.721% |
| Corline Biomedical AB | -1.69 Million SEK | -694.264% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 92.251% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 75.494% |
| Aptahem AB (publ) | -10 Million SEK | -34.186% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 216.296% |
| Fluicell AB (publ) | -25.91 Million SEK | 48.171% |
| Biovica International AB (publ) | -119.5 Million SEK | 88.761% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 68.191% |
| Abliva AB (publ) | -93.6 Million SEK | 85.652% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 95.791% |
| 2cureX AB (publ) | -35.13 Million SEK | 61.774% |
| I-Tech AB | 30.34 Million SEK | 144.261% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 98.12% |
| Cyxone AB (publ) | -20.41 Million SEK | 34.207% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 86.891% |
| Biosergen AB | 228 Thousand SEK | 5990.789% |
| Nanologica AB (publ) | -62.11 Million SEK | 78.379% |
| SynAct Pharma AB | -222.7 Million SEK | 93.969% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 69.378% |
| BioInvent International AB (publ) | -312.7 Million SEK | 95.705% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 4440.8% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 94.201% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -52.409% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 87.628% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -17.107% |